We have 3 of 10 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
An improved NKG2A engager is reported to selectively inhibit NKG2A⁺ NK cells while avoiding activation of NKG2C⁺ subsets, thereby overcoming a key limitation of the natural ligand HLA-E.
Analysis of transcriptomic and flow cytometry analyses and a novel hypoimmune approach improves allogeneic cell persistence by preventing T, B, and NK cell mediated rejection support EngTregs as a potent, stable, and versatile cell therapy platform for autoimmune, inflammatory, and ischemic diseases.
GNTI-932 is a novel, hypoimmune, antigen-specific, off-the-shelf immunotherapy for restoring tolerance in IBD, designed to be scalable and affordable for widespread use.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
